US-based drug delivery systems provider Aptar Pharma has acquired all device technology assets from Israeli medical technology company SipNose Nasal Delivery Systems.
Established in 2011, SipNose specialises in developing intranasal delivery platforms for local, systemic, and central nervous system indications.
The company provides drug delivery devices customised for specific areas of the nasal cavity to improve drug delivery, including direct-to-brain, local, and systemic treatments.
The firm’s expanded delivery systems, including liquid and dry powder intranasal delivery, would further strengthen Aptar Pharma’s nose-to-brain pathway expertise.
Aptar Pharma said that SipNose’s assets will expand its patent product portfolio and support new product development to further support intranasal delivery applications and R&D platforms.
Aptar Pharma Prescription president Alex Theodorakis said: “Our nasal systems’ proven capabilities have brought added value to our customers and further convenience for patients worldwide for over 30 years.
“As the nasal market looks to develop new drugs to address unmet patient needs, this transaction will enhance Aptar’s portfolio of nasal drug delivery systems with a focus on CNS diseases.”
According to SipNose, its intranasal drug delivery platform leverages advanced technology that improves efficacy, patient compliance, and safety.
The platform ensures accurate dose delivery through the nasal cavity, delivering substantially more drug through the upper nasal cavity using compressed air discharge.
It incorporates a simple mechanism to facilitate better localisation of the aerosolised drug in the olfactory epithelium or the trigeminal nerve, resulting in better absorption in the brain.
Aptar Pharma business development director Reenal Gandhi said: “SipNose is focused on development and innovation in intranasal drug delivery. Integrating these assets into our portfolio underlines Aptar Pharma’s continued expansion into the nasal drug delivery space.”
Earlier this year, Aptar Digital Health partnered with SHL Medical to extend SHL’s connected device technologies using its Software as a Medical Device (SaMD) platform.
